# Exploratory Study on Dosage of Qizhi Weitong Granules in the Treatment of Irritable Bowel Syndrome （IBS)

> **NCT05113888** · PHASE2 · UNKNOWN · sponsor: **China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** Qizhi weitong granules(High）
- **DRUG:** Qizhi weitong granules(Low）
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05113888
- **Lead sponsor:** China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-01
- **Primary completion:** 2022-08-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2021-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05113888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05113888, "Exploratory Study on Dosage of Qizhi Weitong Granules in the Treatment of Irritable Bowel Syndrome （IBS)". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT05113888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*